Barrington Research Forecasts Lower Earnings for OPKO Health

OPKO Health, Inc. (NASDAQ:OPK) – Equities research analysts at Barrington Research reduced their Q3 2025 earnings per share (EPS) estimates for OPKO Health in a report issued on Monday, August 4th. Barrington Research analyst M. Petusky now forecasts that the biotechnology company will earn ($0.06) per share for the quarter, down from their previous forecast of ($0.04). Barrington Research has a “Outperform” rating and a $2.25 price objective on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. Barrington Research also issued estimates for OPKO Health’s Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.13) EPS and FY2027 earnings at ($0.11) EPS.

Other equities analysts have also recently issued research reports about the company. LADENBURG THALM/SH SH upgraded OPKO Health to a “strong-buy” rating in a report on Tuesday, July 8th. JPMorgan Chase & Co. started coverage on OPKO Health in a research report on Friday, April 25th. They issued a “neutral” rating for the company. Finally, Wall Street Zen cut shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Monday, May 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $2.75.

OPKO Health Price Performance

NASDAQ OPK opened at $1.27 on Wednesday. OPKO Health has a fifty-two week low of $1.11 and a fifty-two week high of $2.04. The firm has a market cap of $1.01 billion, a P/E ratio of -5.08 and a beta of 1.19. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.41 and a quick ratio of 3.02. The stock’s 50-day moving average is $1.34 and its two-hundred day moving average is $1.47.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The company had revenue of $156.80 million for the quarter, compared to analysts’ expectations of $165.74 million. OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The company’s revenue for the quarter was down 13.9% on a year-over-year basis. During the same period in the prior year, the company earned ($0.01) earnings per share.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of OPK. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of OPKO Health by 4.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock worth $275,000 after acquiring an additional 8,064 shares during the last quarter. Two Sigma Advisers LP lifted its stake in shares of OPKO Health by 2.3% in the 4th quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock valued at $560,000 after purchasing an additional 8,396 shares during the period. Brighton Jones LLC increased its holdings in OPKO Health by 29.1% in the second quarter. Brighton Jones LLC now owns 38,916 shares of the biotechnology company’s stock valued at $51,000 after buying an additional 8,775 shares in the last quarter. 360 Financial Inc. raised its holdings in OPKO Health by 12.0% in the 2nd quarter. 360 Financial Inc. now owns 88,800 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 9,500 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its stake in OPKO Health by 75.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 12,417 shares during the period. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.